Die German Breast Group erforscht Brustkrebs und setzt dafür selbst entwickelte Studienkonzepte um.
Mit zusätzlichen wissenschaftlichen Forschungsprojekten wollen wir weitere Erkenntnisse über die Krankheit gewinnen.
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
We are proud to present our research at ESMO Congress 2022 in Paris.
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer